Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Uterine Cervical Neoplasms 7Brenner Tumor 6Endometrial Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Endometrial Adenocarcinoma 2Cervical Adenocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sertoli-Leydig Cell Tumor 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Immunoglobulin G × Gynecologic × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡